Fennec Pharmaceuticals (FENC) Misses Q4 EPS by 10c

Fennec Pharmaceuticals (NASDAQ: FENC) reported Q4 EPS of ($0.10), $0.10 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $9.73 million versus the consensus estimate of $8.36 million.

For earnings history and earnings-related data on Fennec Pharmaceuticals (FENC) click here.

You May Also Be Interested In

• 'Long-term deals significant positive for stock:' Analysts react to Micron results
• Agilent completes acquisition of Biocare Medical
• Yiren Digital Ltd. (YRD) Reports Q1 Loss of RMB5.64